

Gregory G Schwartz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8595553/publications.pdf>

Version: 2024-02-01

89
papers

13,162
citations

57631

44
h-index

48187

88
g-index

90
all docs

90
docs citations

90
times ranked

11743
citing authors

#	ARTICLE	IF	CITATIONS
1	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
2	Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 1711.	3.8	2,191
3	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	13.9	1,754
4	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2016, 374, 1321-1331.	13.9	877
5	High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study. <i>Circulation</i> , 2003, 108, 1560-1566.	1.6	383
6	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. <i>American Heart Journal</i> , 2014, 168, 682-689.e1.	1.2	365
7	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018, 392, 1311-1320.	6.3	355
8	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	1.2	296
9	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 252.	3.8	270
10	Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2267-2275.	1.2	210
11	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2019, 7, 618-628.	5.5	207
12	Effect of Aloglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1515.	3.8	206
13	High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. <i>European Heart Journal</i> , 2005, 26, 890-896.	1.0	187
14	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009, 158, 896-901.e3.	1.2	184
15	Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction. <i>Circulation</i> , 2002, 106, 1690-1695.	1.6	180
16	Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 372-382.	5.1	158
17	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. <i>Circulation</i> , 2020, 141, 624-636.	1.6	155
18	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	1.2	154

#	ARTICLE	IF	CITATIONS
19	Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2046.	3.8	146
20	Effect of Serial Infusions of CER-001, a Pre- β^2 High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial. <i>JAMA Cardiology</i> , 2018, 3, 815.	3.0	135
21	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 387-396.	1.2	131
22	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1182-1193.	1.2	122
23	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020, 41, 4245-4255.	1.0	117
24	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
25	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. <i>Circulation</i> , 2020, 141, 1608-1617.	1.6	104
26	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1565.	3.8	103
27	Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 109-115.	1.0	92
28	Rationale and Design of the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study ¹¹ See Appendix A for the list of participants in the MIRACL study. That Evaluates Atorvastatin in Unstable Angina Pectoris and in Non-Q-Wave Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 1998, 81, 578-581.	0.7	87
29	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
30	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 164.	3.0	68
31	Relation of Characteristics of Metabolic Syndrome to Short-Term Prognosis and Effects of Intensive Statin Therapy After Acute Coronary Syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. <i>Diabetes Care</i> , 2005, 28, 2508-2513.	4.3	67
32	Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High-Density Lipoprotein. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 7-14.	1.3	60
33	Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 340-348.	5.1	59
34	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	1.2	58
35	Effects of High-Dose Atorvastatin in Patients ≥ 65 Years of Age With Acute Coronary Syndrome (from) <i>Tj ETQq1 1 0.784314 rgBT</i> <i>Journal of Cardiology</i> , 2007, 99, 632-635.	0.7	56
36	PPAR- β as a therapeutic target in cardiovascular disease: evidence and uncertainty. <i>Journal of Lipid Research</i> , 2012, 53, 1738-1754.	2.0	54

#	ARTICLE	IF	CITATIONS
37	Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2017, 135, 1882-1893.	1.6	53
38	PPAR- δ activation fails to provide myocardial protection in ischemia and reperfusion in pigs. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H1314-H1323.	1.5	51
39	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020, 41, 2248-2258.	1.0	51
40	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 45-51.	0.7	49
41	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	1.2	49
42	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	1.2	48
43	Metabolic response of the human heart to inotropic stimulation: In vivo phosphorus-31 studies of normal and cardiomyopathic myocardium. <i>Magnetic Resonance in Medicine</i> , 1992, 25, 260-272.	1.9	46
44	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2021, 143, 1109-1122.	1.6	46
45	Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. <i>Cardiovascular Diabetology</i> , 2021, 20, 13.	2.7	46
46	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	1.2	45
47	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	1.0	45
48	Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. <i>American Heart Journal</i> , 2004, 148, 105.	1.2	42
49	Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 705-716.	2.2	36
50	Existing and emerging strategies to lower Lipoprotein(a). <i>Atherosclerosis</i> , 2022, 349, 110-122.	0.4	36
51	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , 2020, 41, 4114-4123.	1.0	35
52	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
53	PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics. <i>Current Cardiology Reports</i> , 2013, 15, 345.	1.3	33
54	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	0.8	33

#	ARTICLE	IF	CITATIONS
55	Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. <i>Atherosclerosis</i> , 2019, 290, 59-65.	0.4	30
56	High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. <i>American Heart Journal</i> , 2011, 161, 993-999.	1.2	28
57	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. <i>American Heart Journal</i> , 2015, 170, 117-122.	1.2	27
58	Alirocumab after acute coronary syndrome in patients with a history of heart failure. <i>European Heart Journal</i> , 2022, 43, 1554-1565.	1.0	23
59	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	4.3	21
60	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	4.3	19
61	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 330-340.	5.5	19
62	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 14-23.	0.9	18
63	Non-Elastic Deformation of Myocardium in Low-Flow Ischemia and Reperfusion: Ultrastructure-Function Relations. <i>Journal of Molecular and Cellular Cardiology</i> , 1999, 31, 1157-1169.	0.9	17
64	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	0.9	17
65	Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs. <i>Diabetologia</i> , 2017, 60, 1550-1558.	2.9	16
66	New Horizons for Cholesterol Ester Transfer Protein Inhibitors. <i>Current Atherosclerosis Reports</i> , 2012, 14, 41-48.	2.0	15
67	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1703-1715.	1.2	15
68	Thiazolidinedione Drugs Promote Onset, Alter Characteristics, and Increase Mortality of Ischemic Ventricular Fibrillation in Pigs. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 195-204.	1.3	13
69	Dalcetrapib in Patients with an Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2013, 368, 869-870.	13.9	12
70	High-Density Lipoprotein Cholesterol as a Risk Factor and Target of Therapy after Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2009, 104, 46E-51E.	0.7	11
71	Evolving targets for lipid-modifying therapy. <i>EMBO Molecular Medicine</i> , 2014, 6, 1215-1230.	3.3	11
72	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 125.	2.7	11

#	ARTICLE	IF	CITATIONS
73	Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 304, H861-H873.	1.5	9
74	Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis. <i>Journal of Endovascular Therapy</i> , 2018, 25, 624-631.	0.8	9
75	Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 445-458.	1.3	8
76	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1842-1851.	0.8	7
77	Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. <i>Current Opinion in Lipidology</i> , 2022, 33, 147-159.	1.2	7
78	Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 563-572.	1.3	5
79	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. <i>American Heart Journal</i> , 2020, 221, 60-66.	1.2	5
80	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2488-2490.	1.2	4
81	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1542-1549.	0.8	4
82	Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, 101161CIRCGEN121003503.	1.6	3
83	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	2
84	Initiating PCSK9 Inhibition in Hospital for ACS. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2463-2465.	1.2	2
85	Who Should Receive Ezetimibe? —. <i>Journal of the American College of Cardiology</i> , 2017, 69, 922-923.	1.2	1
86	PCSK9 Function and Cardiovascular Death. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3115-3117.	1.2	1
87	Myocardial Infarction and Evolocumab. <i>JAMA Cardiology</i> , 2021, 6, 1220-1221.	3.0	1
88	Response by Schwartz et al to Letter Regarding Article, “Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial”. <i>Circulation</i> , 2020, 142, e335-e336.	1.6	1
89	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. <i>American Journal of Medicine</i> , 2022, , .	0.6	0